Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
First publishedAug 20, 12:01 UTC
Last updatedAug 20, 13:03 UTC · 10m ago
1 outlet
CNBC Top News
1 outlets over time — hover a bar for its window & outletslast updated
Answer
Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.
Reported by 1 outlet — CNBC Top News. See all sources ↓
Read the full report at CNBC Top News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
In brief
- What's the story?
- Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.
- How widely is it covered?
- 1 outlet, average source rating 7.0/10.
- When was it last updated?
- 10m ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
Sources1TypeCoverage
Related in the knowledge graph
Sources (1)
Avg source rating 7.0/10Processing cluster
A1A2A3B1B2B3